ACTRN12610000162011
Completed
Phase 1
A phase I study to determine the safety and tolerability of Dz13 DNAzyme targeting c-Jun in subjects with nodular Basal Cell Carcinoma.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity of New South Wales
- Enrollment
- 9
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically proven nodular BCC.
- •Measurable disease of 8\-16 mm located on trunk or limbs.
- •Presence of dividing cells as identified histologically.
Exclusion Criteria
- •Women of childbearing potential.
- •Prior or co\-existing malignancy.
- •Radiotherapy to \>30% bone marrow in previous three months.
- •Known genetic predisposition to skin cancer.
- •Clinically significant non\-malignant disease.
- •Current immunosuppression.
- •History of immune\-mediated thrombocytopenia or other platelet disease.
- •History of drug abuse.
- •Enrollment in another clinical study using another investigational agent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Phase I study to evaluate the safety and tolerability of single and multiple doses of intranasal pentosan polysulfate (Rhinosul 'Trademark') in healthy subjectsAllergic RhinitisHay feverRespiratory - Other respiratory disorders / diseasesInflammatory and Immune System - AllergiesACTRN12616000676415Paradigm Biopharmaceuticals18
Completed
Not Applicable
A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose subcutaneous and intravenous administration of OMS721 in healthy subjectsautoimmune diseases10003816NL-OMON42466Omeros Corporation24
Completed
Phase 1
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisACTRN12614001199606TB4 Sweden AB30
Completed
Phase 1
Phase I trial to evaluate the safety and tolerability of GDC-0214 in healthy volunteers and patients with mild asthmaAsthmaRespiratory - AsthmaACTRN12617001227381Genentech, Inc.102
Completed
Phase 1
Phase I trial to evaluate the safety and tolerability of GDC-4379 in healthy volunteers and patients with mild asthmaAsthmaRespiratory - AsthmaACTRN12619000227190Genentech128